Key PointsGilead's HIV therapies generate strong free cash flow.

Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.

Key PointsGilead Sciences’ most recent quarterly update was robust.

1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November

Perrigo, a leading provider of consumer self-care products, announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on December 15, 2026, to shareholders of record on Nove

Daily Dividend Report: PRGO,ABBV,MSA,HUM,RTX,GILD

Gilead Sciences, Inc. reported its financial results for the third quarter ended September 30, 2026. Total product sales increased 13% to $8.3 billion compared to the same period in 2025, driven by higher sales of HIV products, Trodelvy, and Livdelzi, and partially offset by lowe

Gilead Sciences, Inc. Reports Third Quarter 2026 Financial Results and Updates Full Year Guidance

(RTTNews) - Gilead Sciences Inc. (GILD) will host a conference call at 4:30 PM ET on October 29, 2026, to discuss Q3 26 earnings results.

Gilead Sciences Q3 26 Earnings Conference Call At 4:30 PM ET 

(RTTNews) - Gilead Sciences, Inc. (GILD) on Tuesday reported it concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on public reimbursement terms for Lyvdelzi (seladelpar), a treatment for primary biliary cholangitis (PBC).

Gilead Reaches Canadian Reimbursement Deal For Liver Disease Drug Lyvdelzi 

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc. News